The use of amphetamine and methylphenidate for the treatment of young people with attention-deficit/hyperactivity disorder (ADHD) was associated with an increased risk for new-onset psychosis, according to results from a study published in the New England Journal of Medicine.
Researchers conducted a retrospective cohort study of 221,846 young people aged 13 to 25 years who were diagnosed with ADHD between 2004 and 2015. Patients were propensity score matched to 1 of 2 treatment groups (methylphenidate or amphetamine; n=110,923 in each), and the incidence of new-onset psychosis was compared between the 2 stimulants. Clinical data were obtained from 2 large, US-based insurance databases, and the results were combined using a fixed-effects meta-analysis.
After analysis, the researchers found a total of 343 cases of psychosis in the matched treatment groups, which included 237 (0.21%) and 106 cases (0.10%) in the amphetamine and methylphenidate groups, respectively. In addition, they reported that the hazard ratio for psychosis in amphetamine group was 1.65 (95% CI, 1.31-2.09).
One key limitation of the study was the presence of unmeasured confounding factors; another was that the findings were not generalizable to patients who have public insurance or no insurance.
“[T]he risk of new-onset psychosis was approximately 1 in 660 patients who received a prescription for stimulants for ADHD, but the risk was about twice as high among patients who started amphetamine as among patients who started methylphenidate,” the researchers wrote.
See source for complete disclosure information.
Moran LV, Ongur D, Hsu J, et al. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019;380(12):1128-1138.